Novartis Ag (NVS) Operating Expenses (2009 - 2025)
Novartis Ag recorded quarterly Operating Expenses of -$6.2 billion in Q2 2025, up 42.45% quarter-over-quarter from -$10.7 billion in Q4 2024, and down 13.03% year-over-year from -$7.1 billion in Q2 2024.
Novartis Ag's Operating Expenses history runs 17 years deep, the most recent figure standing at -$6.2 billion for Q2 2025.
- In Q2 2025, Operating Expenses fell 13.03% year-over-year to -$6.2 billion; the TTM figure through Mar 2026 stood at -$6.2 billion (up 61.87% YoY), while the FY2025 annual figure was $24.4 billion, up 8.23% from the prior year.
- Operating Expenses came in at -$6.2 billion for Q2 2025 at Novartis Ag, up from -$10.7 billion in the prior quarter.
- In the past five years, Operating Expenses ranged from a high of -$672.0 million in Q3 2022 to a low of -$11.9 billion in Q2 2022.
- A 5-year average of -$4.7 billion and a median of -$3.1 billion in 2021 frame the typical range for Operating Expenses.
- Across the five-year window, Operating Expenses tumbled 1273.07% in 2023 and surged 42.14% in 2024, its largest moves.
- Novartis Ag's Operating Expenses stood at -$808.0 million in 2021, then climbed by 2.1% to -$791.0 million in 2022, then sank by 1273.07% to -$10.9 billion in 2023, then gained by 1.31% to -$10.7 billion in 2024, then jumped by 42.45% to -$6.2 billion in 2025.
- According to Business Quant data, Operating Expenses over the past three periods registered -$6.2 billion, -$10.7 billion, and -$5.5 billion for Q2 2025, Q4 2024, and Q2 2024 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Opex (Qtr) |
|---|---|---|---|---|---|
| 1 | Novartis Ag | 107,124,802.25 Bn | 107,124,802.25 Bn | - | - |
| 2 | Eli Lilly | 969.00 Bn | 963.72 Bn | 16.22 Bn | 6.72 Bn |
| 3 | Johnson & Johnson | 539.46 Bn | 517.41 Bn | 15.96 Bn | 9.59 Bn |
| 4 | AbbVie | 376.92 Bn | 367.57 Bn | 10.78 Bn | 11.01 Bn |
| 5 | Merck | 285.00 Bn | 279.35 Bn | 12.09 Bn | 19.82 Bn |
| 6 | Amgen | 177.58 Bn | 165.55 Bn | 5.87 Bn | 5.95 Bn |
| 7 | Gilead Sciences | 163.22 Bn | 155.50 Bn | 5.52 Bn | 4.37 Bn |
| 8 | Pfizer | 145.86 Bn | 133.09 Bn | -1.21 Bn | 5.50 Bn |
| 9 | Bristol Myers Squibb | 111.90 Bn | 101.44 Bn | 8.07 Bn | 8.25 Bn |
| 10 | Gsk | 88.34 Bn | 83.66 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2025 | -6.17 Bn |
| Dec 31, 2024 | -10.72 Bn |
| Jun 30, 2024 | -5.46 Bn |
| Dec 31, 2023 | -10.86 Bn |
| Jun 30, 2023 | -9.43 Bn |
| Mar 31, 2023 | -761.00 Mn |
| Dec 31, 2022 | -791.00 Mn |
| Sep 30, 2022 | -672.00 Mn |
| Jun 30, 2022 | -11.91 Bn |
| Mar 31, 2022 | -721.00 Mn |
| Dec 31, 2021 | -808.00 Mn |
| Sep 30, 2021 | -704.00 Mn |
| Jun 30, 2021 | -6.15 Bn |
| Mar 31, 2021 | -716.00 Mn |
| Dec 31, 2020 | -823.00 Mn |
| Sep 30, 2020 | -704.00 Mn |
| Jun 30, 2020 | -9.30 Bn |
| Mar 31, 2020 | -714.00 Mn |
| Mar 31, 2019 | -756.00 Mn |
| Dec 31, 2018 | -951.00 Mn |
| Sep 30, 2018 | -919.00 Mn |
| Jun 30, 2018 | -6.48 Bn |
| Mar 31, 2018 | -801.00 Mn |
| Dec 31, 2017 | -835.00 Mn |
| Sep 30, 2017 | -836.00 Mn |
| Jun 30, 2017 | -5.87 Bn |
| Mar 31, 2017 | -791.00 Mn |
| Dec 31, 2016 | 9.05 Bn |
| Sep 30, 2016 | -660.00 Mn |
| Jun 30, 2016 | -788.00 Mn |
| Mar 31, 2016 | -759.00 Mn |
| Dec 31, 2015 | -710.00 Mn |
| Sep 30, 2015 | -764.00 Mn |
| Jun 30, 2015 | -601.00 |
| Mar 31, 2015 | -787.00 |
| Dec 31, 2014 | -983.00 |
| Sep 30, 2014 | -808.00 |
| Jun 30, 2014 | -638.00 |
| Mar 31, 2014 | -881.00 |
| Dec 31, 2013 | -695.00 |
| Sep 30, 2013 | -641.00 |
| Jun 30, 2013 | -619.00 |
| Mar 31, 2013 | -761.00 |
| Sep 30, 2012 | -943.00 |
| Jun 30, 2012 | -985.00 |
| Mar 31, 2012 | -967.00 |
| Dec 31, 2011 | -1,041.00 |
| Sep 30, 2011 | -965.00 |
| Jun 30, 2011 | -952.00 |
| Mar 31, 2011 | -904.00 |
| Dec 31, 2010 | -1,016.00 |
| Sep 30, 2010 | -709.00 |
| Jun 30, 2010 | -702.00 |
| Mar 31, 2010 | -2,607.00 |
| Dec 31, 2009 | -7.47 Bn |
| Sep 30, 2009 | -2,367.00 |
| Jun 30, 2009 | -2,344.00 |
| Mar 31, 2009 | -2,199.00 |